MySugarWatch Continues Large-Scale Awareness Campaign Around Nemaura Medical’s sugarBEAT Non-Invasive Continuous Glucose Monitor Commencing Direct-to-Consumer Campaign in Daily Mail
May 17 2022 - 8:00AM
Nemaura Medical, Inc. (Nasdaq: NMRD), a medical technology company
focused on developing and commercializing wearable diagnostic
devices and supporting personalized lifestyle coaching programs,
announces today that its UK licensee, MySugarWatch, has continued
its large scale awareness campaign for the Company’s sugarBEAT
non-invasive continuous glucose monitor by commencing a
direct-to-consumer campaign in one of the UK’s largest daily
newspaper, Daily Mail.
MySugarWatch’s Daily Mail campaign is designed
to reach its more than 1.2 million daily readers, inviting them to
learn more about glucose management as part of sugarBEAT
commercialization by Nemaura’s UK licensee. The Daily Mail ads are
part of a previously announced wider campaign, which also targets
media outlets geared toward both consumers and professionals.
Faz Chowdhury, Ph.D., Nemaura’s CEO commented,
“Embarking on the consumer phase of our UK licensee’s campaign in
support of the commercialization efforts around sugarBEAT is very
exciting and we are looking forward to continuing our support for
our licensee. Our commitment to supporting MySugarWatch’s success
remains strong, and we look forward to the opportunity to provide
what is potentially a game-changing non-invasive CGM, to potential
users in the UK.”
About Nemaura Medical, Inc.
Nemaura Medical, Inc. is a medical technology
company developing and commercializing wearable diagnostic devices.
The company is currently commercializing sugarBEAT® and
proBEAT™. sugarBEAT®, a CE mark approved Class IIb medical device,
is a non-invasive and flexible continuous glucose monitor (CGM)
providing actionable insights derived from real time glucose
measurements and daily glucose trend data, which may help people
with diabetes and pre-diabetes to better manage, reverse, and
prevent the onset of diabetes. Nemaura has submitted a PMA
(Premarket Approval Application) for sugarBEAT® to the U.S.
FDA. proBEAT™ combines non-invasive glucose data processed
using artificial intelligence and a digital healthcare subscription
service and has been launched in the U.S. as a general wellness
product as part of its BEAT®diabetes program that is currently
undergoing pilot studies.
Additionally, Nemaura has launched Miboko, a new
metabolic health and well-being program using a non-invasive
glucose sensor along with an AI mobile application that helps a
user understand how certain foods and lifestyle habits can impact
one’s overall metabolic health and well-being. Nemaura believes
that up to half the population could benefit from a sensor and
program that monitors metabolic health and well-being.
The Company sits at the intersection of the
global Type 2 diabetes market that is expected to reach nearly $59
billion by 2025, the $50+ billion pre-diabetic market, and the
wearable health-tech sector for weight loss and wellness
applications that is estimated to reach $60 billion by 2023.
For more information, please visit www.NemauraMedical.com.
Contact:
Jules AbrahamCORE IR917-885-7378julesa@coreir.com
Nemaura Medical (NASDAQ:NMRD)
Historical Stock Chart
From Jun 2024 to Jul 2024
Nemaura Medical (NASDAQ:NMRD)
Historical Stock Chart
From Jul 2023 to Jul 2024